However, despite promising results44,46 and an ongoing phase 1 trial of 1D11 in osteogenesis imperfecta (https://clinicaltrials.gov/ct2/show/NCT03064074), serious toxicities have hampered progress44,46, and no TGFβ inhibitor has received FDA approval. Here, TGFB1 is linked to osteogenesis imperfecta.